|
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV |
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. PharmacoEconomics 2010; 28(11): 1025-1039 Indexing Status Subject indexing assigned by NLM MeSH Adenine /analogs & Adult; Anti-HIV Agents /economics /therapeutic use; Antiretroviral Therapy, Highly Active /economics; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Dideoxynucleosides /adverse effects /economics /therapeutic use; Drug Hypersensitivity /genetics; Drug-Related Side Effects and Adverse Reactions /economics /therapy; Genetic Testing /economics; HIV Infections /drug therapy /economics; HLA-B Antigens /genetics; Humans; Middle Aged; Models, Economic; Organophosphonates /economics /therapeutic use; Quality-Adjusted Life Years; Tenofovir; United States; derivatives /economics /therapeutic use AccessionNumber 22010001945 Date bibliographic record published 20/10/2011 |
|
|
|